Comprehensive characterization and clinical impact of concomitant genomic alterations in EGFR-mutant NSCLCs treated with EGFR kinase inhibitors

Ying Cheng,Lixia Ma,Ying Liu,Jing Zhu,Ying Xin,Xianhong Liu,Ying Wang,Tingting Zhang,Changliang Yang,Sheng Wang,Hongxia Cui,Liang Zhang,Jixin Dai,Lin Shao,Jing Lin,Junyi Ye,Hao Liu

Lung Cancer（2020）

引用 19|浏览63

暂无评分

摘要

•Alterations in TP53, ERBB2 or FGF19 correlated with poorer prognosis in TKI1st treated NSCLCs.•EGFR-mutant and TP53-WT NSCLCs benefited more from the combined A + T therapy.•NSCLC patients with CNV correlated with a shorter PFS in response to TKI3rd.

查看译文

关键词

EGFR tyrosine kinase inhibitors,EGFR-mutant-NSCLC,Progression-free survival,Overall survival,Genomic alterations

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要